Patient-specific tumor-associated antigens (TSA)

Patient-specific tumor-associated antigens, commonly known as neoantigens, are unique peptides derived from non-synonymous somatic mutations occurring within a specific patient's tumor (Schumacher & Schreiber, 2015). These antigens are absent from the normal genome, making them ideal targets for immunotherapy as they minimize the risk of central thymic tolerance and off-target autoimmune damage (Ott et al., 2017). In dendritic cell (DC) therapy, these antigens are either loaded onto autologous DCs ex vivo or targeted to DCs in vivo to facilitate robust presentation via Major Histocompatibility Complex (MHC) molecules (Banchereau & Steinman, 1998). This presentation triggers the activation and proliferation of antigen-specific CD4+ and CD8+ T-cells, which then circulate and infiltrate the tumor microenvironment to execute targeted lysis of malignant cells (Saxena et al., 2021). Because neoantigens vary significantly between individuals, this approach represents a cornerstone of personalized precision medicine in oncology. Current clinical applications focus on high-mutational burden cancers like melanoma and non-small cell lung cancer, often utilizing platforms such as mRNA vaccines or pulsed dendritic cell lysates (Sahin & Türeci, 2018).

Other names

NeoantigensTumor-specific antigensPersonalized tumor antigensMutated neoantigensTSAs

Activation of the adaptive immune system by presenting unique tumor-derived peptides to T-cells via MHC molecules on dendritic cells, leading to the generation of cytotoxic T-lymphocytes that specifically target and eliminate tumor cells.